- Report
- January 2022
- 60 Pages
Global
From €3618EUR$3,950USD£3,075GBP
- Report
- January 2022
- 60 Pages
Global
From €3618EUR$3,950USD£3,075GBP
- Report
- January 2022
- 60 Pages
Global
From €3618EUR$3,950USD£3,075GBP
- Report
- September 2022
- 120 Pages
Global
From €2290EUR$2,500USD£1,946GBP
- Report
- February 2024
- 110 Pages
Global
From €4351EUR$4,750USD£3,698GBP
- Report
- February 2024
- 120 Pages
Global
From €4351EUR$4,750USD£3,698GBP
- Drug Pipelines
- February 2023
- 127 Pages
Global
From €13736EUR$14,995USD£11,674GBP
- Report
- November 2021
- 70 Pages
Global
From €3206EUR$3,500USD£2,725GBP
- Report
- August 2022
United States
From €1777EUR$1,940USD£1,510GBP
- Report
- August 2022
Global
From €999EUR$1,090USD£849GBP
- Report
- December 2023
- 182 Pages
Global
€4576EUR$4,995USD£3,889GBP
- Report
- February 2021
- 35 Pages
Global
€1207EUR$1,318USD£1,026GBP
- Report
- October 2024
- 96 Pages
Global
From €3500EUR$4,093USD£3,079GBP
- Report
- February 2024
- 101 Pages
Global
From €3500EUR$4,093USD£3,079GBP
- Report
- July 2022
- 51 Pages
Global
From €3206EUR$3,500USD£2,725GBP
- Report
- May 2022
- 122 Pages
Global
From €1832EUR$2,000USD£1,557GBP
- Report
- May 2022
- 75 Pages
Global
From €1832EUR$2,000USD£1,557GBP
- Report
- December 2023
- 279 Pages
Global
From €2366EUR$2,583USD£2,011GBP
€3380EUR$3,690USD£2,873GBP

The Neuropathic Pain Drug market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological disorders. Neuropathic pain drugs are used to treat chronic pain caused by nerve damage, such as diabetic neuropathy, postherpetic neuralgia, and trigeminal neuralgia. These drugs are typically divided into two categories: anticonvulsants and antidepressants. Anticonvulsants are used to reduce the intensity of nerve pain, while antidepressants are used to reduce the frequency of nerve pain. Commonly prescribed neuropathic pain drugs include pregabalin, gabapentin, duloxetine, and amitriptyline.
Some companies in the Neuropathic Pain Drug market include Pfizer, GlaxoSmithKline, Eli Lilly, and Novartis. Show Less Read more